Ann: Ischemic End Stage HF Outcomes at Virtual ACC Annual Meeting, page-20

Unfortunately I think that is a result of it being labelled a non-sensitive market announcement that was made after lunch.

Techinvestor is right, this is from the 'failed' trial from November 2018. In the original paper this effect was mentioned with respect to the ischaemic subgroup, but it was more or less lost within the supposed 'failure' of the trial. Certainly the editorial that accompanied the original paper did not make any mention of this and instead threw a huge wet blanket over the whole endeavour. However, the actual authors did note at the time that this was an avenue worth pursuing and, personally, the mention of it in the original paper was what kept me invested in MSB after that blunder. The stats are clearly in MSB's favour in this instance, but as with all trials take any post-hoc analysis with a grain of salt (or at least that will be what all the naysayers will advise). DYOR.